ImmunityBio, Inc.
IBRX
$7.77
-$0.29-3.60%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 63.59% | -921.54% | 7.89% | 27.34% | 28.61% |
| Total Depreciation and Amortization | 0.62% | 16.33% | -4.71% | 1.83% | 1.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -71.12% | 26,146.70% | -68.65% | -53.55% | -76.62% |
| Change in Net Operating Assets | 17.40% | 96.53% | -16.83% | -122.04% | 74.79% |
| Cash from Operations | 11.76% | -7.08% | -2.13% | 13.59% | 7.17% |
| Capital Expenditure | -97.97% | -96.68% | -21.86% | 31.45% | 3.57% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -247.97% | -167.17% | 124.62% | -1,099.26% | -386.88% |
| Cash from Investing | -239.55% | -172.64% | 124.03% | -1,023.53% | -490.94% |
| Total Debt Issued | -100.07% | 2,502.67% | -- | -- | -- |
| Total Debt Repaid | -1.93% | 22.99% | -9,433.33% | -200.00% | -- |
| Issuance of Common Stock | -70.83% | 191.64% | -69.06% | 0.32% | 78,598.18% |
| Repurchase of Common Stock | 95.44% | -1,085.42% | -290.73% | 53.11% | 73.21% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -80.15% | 307.92% | -68.36% | 0.41% | 17,697.76% |
| Foreign Exchange rate Adjustments | -102.46% | 2,340.00% | 108.93% | -173.68% | 860.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -210.67% | 316.60% | 136.58% | -199.75% | 193.03% |